Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Miscellaneous

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or
the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601
monotherapy and in combination with gemcitabine.
Miscellaneous
I
Davis, Elizabeth
NCT05389462
VICCPHI2225

Blood based biomarkers for minimal residual disease detection in Pediatric Sarcomas

Multiple Cancer Types

Pediatrics, Sarcoma
N/A
Borinstein, Scott
VICCPED2160

CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan.

Multiple Cancer Types

Pediatrics, Sarcoma
N/A
Friedman, Debra
VICCPED2222

Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)

Melanoma

Melanoma
N/A
Zwerner, Jeffrey
VICCDERM22117

Centers for Disease Control and Prevention - Community Counts: Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting

Benign Hematologic

Benign Hematologic
N/A
Chi, Michelle
NCBH2301-CDC-REGISTRY

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Multiple Cancer Types

Neuroblastoma (Pediatrics), Pediatric Solid Tumors
N/A
Kitko, Carrie
NCT01590680
VICCPED1249


Blood-based, Point-of-need Assessment of CAR-T Vector Load in DLBCL Patients Undergoing Axicabtagene Ciloleucel (axi-cel) Therapy: A Multi-Site Study

Lymphoma

Lymphoma
N/A
Oluwole, Olalekan
VICC-IDCTT23426

Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma

Multiple Cancer Types

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Leukemia, Pediatric Leukemia
III
Borinstein, Scott
NCT05602194
VICC-NTPED23475

Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD

Multiple Cancer Types

This phase II trial studies the treatment response for patients with acute graft-versus-host disease (GVHD). GVHD occurs when donor immune cells attack the healthy tissue of a bone marrow or stem cell transplant patient. The standard treatment for GVHD is to lower the activity of the donor cells by using steroid medications such as prednisone. But steroid treatment may cause many complications and the risk of these complications increases with higher doses of steroids and longer treatment. It is important to find ways to decrease the steroid treatment in patients who do not need long courses. Researchers are doing this study to find out how many subjects respond well to lower steroid dosing based on a blood test (GVHD biomarker) and if they develop fewer complications.
Miscellaneous, Pediatrics
II
Kitko, Carrie
NCT05090384
VICCPED2213

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.